Targeting neuroinflammation with minocycline in heavy drinkers | Zendy

Ismene L. Petrakis | Zendy; Elizabeth Ralevski | Zendy; Ralitza Gueorguieva | Zendy; Matthew E. Sloan | Zendy; Lesley Devine | Zendy; Gihyun Yoon | Zendy; Albert J. Arias | Zendy; Mehmet Sofuoglu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting neuroinflammation with minocycline in heavy drinkers

Author(s) -

Ismene L. Petrakis,

Elizabeth Ralevski,

Ralitza Gueorguieva,

Matthew E. Sloan,

Lesley Devine,

Gihyun Yoon,

Albert J. Arias,

Mehmet Sofuoglu

Publication year - 2019

Publication title -

psychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.378

H-Index - 196

eISSN - 1432-2072

pISSN - 0033-3158

DOI - 10.1007/s00213-019-05205-3

Subject(s) - minocycline , neuroinflammation , pharmacology , placebo , ethanol , medicine , microglia , cytokine , craving , inflammation , anesthesia , immunology , antibiotics , chemistry , pathology , psychiatry , biochemistry , addiction , alternative medicine

Alcohol has both acute and chronic effects on neuroimmune signaling, including triggering pro-inflammatory cytokine release by microglia. Minocycline, a second-generation tetracycline antibiotic, inhibits microglial activation and reduces neuroinflammation in preclinical studies. In mice, minocycline also reduces ethanol intake, attenuates ethanol-induced conditioned place preference, and inhibits ethanol-induced microglial activation and pro-inflammatory cytokine release.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research